To develop and improve such therapeutic approaches it will be key to further elucidate the spatial localization and timepoints of IDO1 induction within tumor compartments or the TME during processes such as anti-tumoral immune responses and tumor progression. This evidence concerns the gene IDO1 and neoplasm.